One A Day Raises Biotin Dose in Women's Multi Gummy Reformulation

Bayer has introduced a reformulated version of One A Day Women's Multi Gummy featuring a substantially higher biotin dose, positioning the change around consumer demand for supplements that combine general nutritional support with hair, skin, and nail benefits in a single product.¹

For finished product manufacturers, the move is a notable data point in a competitive multivitamin gummy category where dosage comparisons against named competitors, rather than clinical substantiation alone, are increasingly part of the marketing strategy.

"Women are increasingly looking for products that simplify their wellness routines while delivering benefits that fit their evolving health and beauty needs," commented Lisa Perez, general manager and vice president of marketing at Bayer. "Our new formula of Women's Multi Gummies helps consumers support their daily nutritional needs alongside healthy hair, skin and nails in one serving of our delicious gummies."

What Does the Reformulated Product Contain?

The new formula delivers 1,000 mcg of biotin per serving alongside vitamins A, C, E, and zinc, ingredients the company positions specifically for hair, skin, and nail support. Beyond that combination, the product is formulated to address 6 additional areas, physical energy metabolism through B vitamins and biotin, bone health via vitamin D, heart health through folic acid and vitamins B6 and B12, immune function through vitamins A, C, D, E, and zinc, and muscle function through vitamin D. The company notes its heart health claim is not a replacement for heart medications, language required to avoid implying a therapeutic substitute.

How Strong Is the Evidence for Biotin Supplementation Specifically?

Independent dermatology literature offers a more measured picture than typical biotin marketing suggests. A 2024 systematic review published in the Journal of Clinical and Aesthetic Dermatology searched the literature for human studies evaluating biotin monotherapy for hair growth and identified only three studies meeting rigorous inclusion criteria; the single highest-quality trial, a double-blind, placebo-controlled study, found no difference between biotin and placebo groups for hair growth.²

The review's authors noted a substantial gap between biotin's popularity as a hair supplement and the strength of evidence actually supporting it. This distinction matters for how manufacturers and consumers alike should interpret dose comparisons: a substantially higher biotin dose does not, on its own, equate to a substantially stronger clinical outcome, since the underlying evidence gap applies regardless of dose in a population without diagnosed deficiency.

Why Do Multivitamin Brands Compete on Biotin Dosage Specifically?

Biotin has become one of the more commonly marketed ingredients in the hair, skin, and nails supplement category, in part because consumer awareness of the ingredient is high relative to more heavily substantiated alternatives. That awareness creates a competitive incentive to differentiate primarily through dose comparison, as reflected in Bayer's direct percentage comparison against three named competitor products.

For formulators and brand managers evaluating similar positioning strategies, the more clinically defensible approach, consistent with dermatology literature, involves combining biotin with other standardized, multi-targeting ingredients rather than relying on biotin dose alone as the primary substantiation for a hair or nail health claim.

What Should Manufacturers and Consumers Understand About This Kind of Reformulation?

The removal of artificial sweeteners, high fructose corn syrup, and FD&C color additives reflects a broader clean-label trend across the gummy vitamin category, distinct from the biotin dosage change and not itself tied to any specific clinical claim. As with all structure-function claims on dietary supplements, the product's hair, skin, and nail support statements carry the standard FDA disclaimer indicating the claims have not been evaluated by the agency and are not intended to diagnose, treat, cure, or prevent disease.

References

1. Bayer. One A Day introduces new Women's Multi Gummy formula with 1,000 mcg biotin. Business Wire. July 28, 2026. Accessed August 3, 2026. https://www.businesswire.com/news/home/20260728608018/en/One-A-Day-Introduces-New-Womens-Multi-Gummy-Formula-with-1000-mcg-Biotin

2. Yelich A, Jenkins H, Holt S, Miller R. Biotin for hair loss: teasing out the evidence. J Clin Aesthet Dermatol. 2024;17(8):56-61.